Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer

Pancreatic cancer is a devastating disease with a poor prognosis. Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments. Lurbinectedin (PM01183; LY-01017) received FDA approval in 2020 for metastatic small cell lung cancer on or afte...

Descripción completa

Detalles Bibliográficos
Autores principales: Tummala, Tej, Sevilla Uruchurtu, Ashley Sanchez, Cruz, Arielle De La, Huntington, Kelsey E., George, Andrew, Liguori, Nicholas R., Zhang, Leiqing, Zhou, Lanlan, Abbas, Abbas E., Azzoli, Christopher G., El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670398/
https://www.ncbi.nlm.nih.gov/pubmed/37999116
http://dx.doi.org/10.3390/curroncol30110696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10670398/
https://www.ncbi.nlm.nih.gov/pubmed/37999116
http://dx.doi.org/10.3390/curroncol30110696

Ejemplares similares